Nature Medicine, Published online: 25 February 2025; doi:10.1038/s41591-025-03583-0
A sustained decrease in low-density lipoprotein cholesterol (LDL-C) is key to reducing the risk of atherosclerotic cardiovascular disease; however, achieving this goal can be hampered by low adherence to standard of care and the sub-maximal efficacy of currently available long-acting therapeutics. We developed an epigenetic editor that targets PCSK9 and robustly and durably decreases LDL-C.
